CT-XEROX
25.6.2020 14:39:04 CEST | Business Wire | Press release
Today, Xerox announced the launch of its Team Availability App , a quick-to-deploy, real-time solution for organizations that need to understand employee availability and location. Knowing where and whether employees are working is critical to managing flexible work environments, where the percentage of employees sharing time between home and work locations grows.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005437/en/
Organizations are actively supporting and investing in technology solutions for a hybrid workforce. A recent global business survey commissioned by Xerox shows 58% of respondents plan to change their work from home policy within the next year. This new acceptance of a hybrid workforce has also revealed technology gaps, with companies increasing investment in remote technology resources (55%) or a hybrid of remote and in-office resources (40%).
"Managing a distributed workforce during a continued pandemic presents unique challenges no organization has experienced before," said Joanne Collins Smee, executive vice president and chief commercial, SMB and channels officer, Xerox. "Organizations need to know who is available and where so they can make better decisions when allocating resources and work. This tool provides real-time knowledge to managers with distributed employee populations."
Unlike other attendance management tools, which need to plug into IT infrastructure and take weeks to implement, the Team Availability App is ready in just hours. Once populated, the app provides authorized users with customizable and privacy-protected data for strategic decision making. Xerox is rolling out the app across the company to support its Path Forward plans to manage a phased approach to returning to the workplace safely. Xerox is leveraging the app with its own employee population to conduct daily health checks for exposure related to COVID-19. Tracking of this activity allows for a safe and phased return to the workplace.
The U.K.'s prestigious Imperial NHS Trust was the first organization to pilot the Xerox Team Availability App to access the status of essential workers across the Trust and its newly assigned locations at the height of the pandemic.
"It's important for a healthcare provider to know which caregivers are available when to support patients, and that's even more critical in a pandemic," said Linda Watts, joint clinical systems program manager, Imperial NHS Trust & Chelsea & Westminster NHS Foundation Trust, head of health records, Imperial College Healthcare NHS Trust. "The Xerox Team Availability App was deployed at lightning speed, and we got updates from staff on their availability in real-time. As a result, we could always make sure our patients were covered."
The Xerox Team Availability App is a GDPR-compliant SaaS offering with a subscription-based model that allows customers to sign up for as long as required. It's available now on the App Store and Google Play Store .
For more information and additional results from the Xerox Future of Work study, visit www.Xerox.com/MakeNowWork .
About Xerox
Xerox makes every day work better. We are a workplace technology company building and integrating software and hardware for enterprises large and small. As customers seek to manage information across digital and physical platforms, Xerox delivers a seamless, secure and sustainable experience. Whether inventing the copier, the ethernet, the laser printer or more, Xerox has long defined the modern work experience. Learn how that innovation continues at xerox.com .
Xerox Future of Work Survey Methodology
The survey of 600 respondents located in the U.S., Canada, UK, Germany and France was conducted by independent research firm Vanson Bourne in May 2020. Respondents included IT decision-makers (including senior C-level professionals), all from organizations with at least 500 employees across a range of sectors, including business and professional services, retail, health care, financial services, and travel and hospitality.
Note: To receive RSS news feeds, visit https://www.news.xerox.com . For open commentary, industry perspectives and views, visit http://twitter.com/xerox , http://www.facebook.com/XeroxCorp , https://www.instagram.com/xerox/ , http://www.linkedin.com/company/xerox , http://www.youtube.com/XeroxCorp .
Xerox® is a trademark of Xerox Corporation in the United States and/or other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005437/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 11:30:00 CET | Press release
Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural wo
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release
Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom